Category - Developments

Developments

Dresner Partners opens office in Florida

Dresner Partners has opened a new office in Fort Lauderdale, FL to be headed by Mitchell Stern, managing director and head of Dresner Partners’ healthcare practice. Mr. Stern will also continue to spend a portion of...

September 27, 2016

Developments

FDA grants orphan drug status to Soricimed’s SOR-C13

The FDA has granted orphan drug designation to closely-held Soricimed Biopharma’s peptide, SOR-C13, for the treatment of pancreatic cancer, following a similar designation for ovarian cancer In a statement, Paul Gunn...

September 27, 2016

Developments

Mateon collaborates with US Oncology Research

US Oncology Research will participate in Mateon Therapeutics’ (NASDAQ:MATN) FOCUS clinical trial in platinum-resistant ovarian cancer. In a statement, Dr. William Schwieterman, president and CEO of Mateon, said US...

September 26, 2016

Developments

Global Kinetics gets FDA okay for Parkinson’s KinetiGraph

Australia-based Global Kinetics has received 510(k) marketing clearance from the FDA for its next generation, wrist-worn Parkinson’s KinetiGraph (PKG) System. The new PKG technology enables a shift to “anywhere...

September 22, 2016

Developments

Profound Medical treats first patient in TACT pivotal trial

The first patient has been treated in Profound Medical’s (TSX-V:PRN) TACT pivotal trial at Vanderbilt University Medical Center in Nashville, TN. TACT is a prospective, single-arm pivotal clinical study of 110 patients...

September 22, 2016

Developments

Appeals court upholds LifeNet’s patent victory

The U.S. Court of Appeals for the Federal Circuit upheld a Virginia federal jury award to LifeNet Health of $34.7-million in damages for LifeCell’s infringement of a LifeNet patent related to improving the...

September 19, 2016

Developments Markets

TearLab to request NASDAQ hearing over listing

TearLab (NASDAQ:TEAR; TSX:TLB) has received a letter from the Nasdaq listing qualifications staff, indicating that the company failed to regain compliance with the $1 minimum bid price requirement for continued listing...

September 19, 2016

Developments

M Pharma posts successful pilot studies

M Pharmaceutical (OTCQB:MPHMF; CSE:MQ) announced findings from the third of three proprietary pilot studies related to the recently acquired Chelatexx technology, or the company’s C-103 project. The third study...

September 15, 2016

Developments

Vital Therapies updates Phase 3 trial

In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company’s Phase 3 trial, designed to evaluate the ELAD System in...

September 14, 2016

Developments

AmorChem spins out CD36 technology into Mperia Therapeutics

Closely-held AmorChem has spun out Mperia Therapeutics, a start-up company focusing on a novel immunotherapy approach based on CD36 cell receptor drug-ligands. All rights to the CD36 technology initially held by...

September 12, 2016

Category - Developments

Subscribe